BACKGROUND: @entity1479 shocks are potentially associated with @entity296 , altered hemodynamics, apoptosis and inflammatory signaling. Their precise cellular impact can be explored after defibrillation testing (DFT) via biomarkers. We evaluated changes in biomarkers after @entity1479 shocks during DFT. METHODS: We prospectively enrolled outpatients presenting for first implantation of a cardiac device. Biomarkers indicative of @entity296 , @entity32 and apoptosis were measured before and after implantation, and compared between @entity1 receiving DFT (DFT+) to those not (DFT-). RESULTS: Sixty-three @entity1 were enrolled, 40 in the DFT+ group and 23 in the DFT- group. Average levels of troponin I, hsCRP, @entity1190 , NTproBNP, and sFas increased by >50% after cardiac device implantation compared to baseline. Increase in troponin never exceeded 50 fold upper limit of normal (2ng/mL). Troponin trended higher in the DFT+ group at 8 hours (median 0.18 ng/mL, IQR 0.11-0.48) versus the DFT- group (0.10 ng/mL, IQR 0.06-0.28, P = 0.0501); NTproBNP had a similar trend (p = 0.0581). sFas significantly increased in the DFT+ group from baseline (median 4663 pg/mL, IQR 2908-5679) to 24 hours (5039 pg/mL, IQR 3274-6261;p = 0.0338) but not in the DFT- group (p = 0.4705). CONCLUSION: DFT testing is associated with acutely increased plasma levels of troponin and sFas, a biomarker of apoptosis, along with a trend towards higher NTproBNP. This article is protected by copyright. All rights reserved.

Acute Effects of Implantable Cardioverter-Defibrillator Shocks on Biomarkers of @entity296 , Apoptosis, Heart Failure, and XXXX .

@entity1479 :: ('OMIM:252500', 'Disease') :: ['ICD'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial injury'] @entity1190 :: ('MESH:D039841', 'Chemical') :: ['Calprotectin']
@entity32 :: (MESH:D007249,Disease) :: ['Systemic Inflammation']
